Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study.
Saved in:
| Title: | Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study. |
|---|---|
| Authors: | Gossec, Laure1,2 (AUTHOR) laure.gossec@aphp.fr, Baraliakos, Xenofon3 (AUTHOR), Galloway, James4 (AUTHOR), Oke, Vilija5 (AUTHOR), Sfikakis, Petros6 (AUTHOR), Rampakakis, Emmanouil7,8 (AUTHOR), Sharaf, Mohamed9 (AUTHOR), Lavie, Frederic10 (AUTHOR), McInnes, Iain B.11 (AUTHOR) |
| Source: | Rheumatology & Therapy. Apr2026, Vol. 13 Issue 2, p347-360. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21986576 |
|---|---|
| DOI: | 10.1007/s40744-025-00821-2 |
